BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

968 related articles for article (PubMed ID: 33562193)

  • 21. COVID-19 and cardiovascular diseases.
    Liu F; Liu F; Wang L
    J Mol Cell Biol; 2021 Jul; 13(3):161-167. PubMed ID: 33226078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of angiotensin-converting enzyme 2 in neurodegenerative diseases during the COVID-19 pandemic.
    Li Z; Xu X; Yang M; Feng J; Liu C; Yang C
    Aging (Albany NY); 2020 Nov; 12(23):24453-24461. PubMed ID: 33197881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioinformatics and system biology approach to identify the influences of COVID-19 on cardiovascular and hypertensive comorbidities.
    Nashiry A; Sarmin Sumi S; Islam S; Quinn JMW; Moni MA
    Brief Bioinform; 2021 Mar; 22(2):1387-1401. PubMed ID: 33458761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thyroid complications of SARS and coronavirus disease 2019 (COVID-19).
    Speer G; Somogyi P
    Endocr J; 2021 Feb; 68(2):129-136. PubMed ID: 33473054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19 and Cardiovascular Disease: From Bench to Bedside.
    Chung MK; Zidar DA; Bristow MR; Cameron SJ; Chan T; Harding CV; Kwon DH; Singh T; Tilton JC; Tsai EJ; Tucker NR; Barnard J; Loscalzo J
    Circ Res; 2021 Apr; 128(8):1214-1236. PubMed ID: 33856918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiology and COVID-19: do we have sufficient information?
    Garg N; McClafferty B; Ramgobin D; Golamari R; Jain R; Jain R
    Future Cardiol; 2021 Jul; 17(4):705-711. PubMed ID: 33124920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ACE2 Is an Adjacent Element of Atherosclerosis and COVID-19 Pathogenesis.
    Poznyak AV; Bezsonov EE; Eid AH; Popkova TV; Nedosugova LV; Starodubova AV; Orekhov AN
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science.
    Evans PC; Rainger GE; Mason JC; Guzik TJ; Osto E; Stamataki Z; Neil D; Hoefer IE; Fragiadaki M; Waltenberger J; Weber C; Bochaton-Piallat ML; Bäck M
    Cardiovasc Res; 2020 Dec; 116(14):2177-2184. PubMed ID: 32750108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of morbidity and mortality in COVID-19.
    Gacche RN; Gacche RA; Chen J; Li H; Li G
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1684-1707. PubMed ID: 33629339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cardiovascular aspect of COVID-19.
    Adu-Amankwaah J; Mprah R; Adekunle AO; Ndzie Noah ML; Adzika GK; Machuki JO; Sun H
    Ann Med; 2021 Dec; 53(1):227-236. PubMed ID: 33345626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular Outcomes in the Acute Phase of COVID-19.
    Nakano H; Shiina K; Tomiyama H
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports.
    Soumya RS; Unni TG; Raghu KG
    Cardiovasc Drugs Ther; 2021 Jun; 35(3):411-425. PubMed ID: 32926272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endothelial Dysfunction as a Primary Consequence of SARS-CoV-2 Infection.
    Mezoh G; Crowther NJ
    Adv Exp Med Biol; 2021; 1321():33-43. PubMed ID: 33656711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics.
    Choi HM; Moon SY; Yang HI; Kim KS
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COVID-19 and cardiovascular disease: manifestations, pathophysiology, vaccination, and long-term implication.
    Abdel Moneim A; Radwan MA; Yousef AI
    Curr Med Res Opin; 2022 Jul; 38(7):1071-1079. PubMed ID: 35575011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathophysiological Association of Endothelial Dysfunction with Fatal Outcome in COVID-19.
    Maruhashi T; Higashi Y
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34066226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COVID-19 and cardiovascular disease: a review of current knowledge.
    Pal A; Ahirwar AK; Sakarde A; Asia P; Gopal N; Alam S; Kaim K; Ahirwar P; Sorte SR
    Horm Mol Biol Clin Investig; 2021 Feb; 42(1):99-104. PubMed ID: 33544511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of SARS-CoV-2 target ACE2 in cardiovascular diseases.
    Zhu H; Zhang L; Ma Y; Zhai M; Xia L; Liu J; Yu S; Duan W
    J Cell Mol Med; 2021 Feb; 25(3):1342-1349. PubMed ID: 33443816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS-CoV-2, Cardiovascular Diseases, and Noncoding RNAs: A Connected Triad.
    Natarelli L; Virgili F; Weber C
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA).
    Cenko E; Badimon L; Bugiardini R; Claeys MJ; De Luca G; de Wit C; Derumeaux G; Dorobantu M; Duncker DJ; Eringa EC; Gorog DA; Hassager C; Heinzel FR; Huber K; Manfrini O; Milicic D; Oikonomou E; Padro T; Trifunovic-Zamaklar D; Vasiljevic-Pokrajcic Z; Vavlukis M; Vilahur G; Tousoulis D
    Cardiovasc Res; 2021 Dec; 117(14):2705-2729. PubMed ID: 34528075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.